Search results
Results from the WOW.Com Content Network
Dimethyldichlorosilane hydrolyzes to form linear and cyclic silicones, compounds containing Si-O backbones.The length of the resulting polymer is dependent on the concentration of chain ending groups that are added to the reaction mixture.
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
The following is a list of antibiotics. The highest division between antibiotics is bactericidal and bacteriostatic. Bactericidals kill bacteria directly, whereas bacteriostatics prevent them from dividing. However, these classifications are based on laboratory behavior.
This is a list of common β-lactam antibiotics—both administered drugs and those not in clinical use—organized by structural class. Antibiotics are listed alphabetically within their class or subclass by their nonproprietary name. If an antibiotic is a combination drug, both ingredients will be listed.
This list categorises drugs alphabetically and also by other categorisations. This multi-page article lists pharmaceutical drugs alphabetically by name. Many drugs have more than one name and, therefore, the same drug may be listed more than once.
This multi-page article lists pharmaceutical drugs alphabetically by name. Many drugs have more than one name and, therefore, the same drug may be listed more than once. Brand names and generic names are differentiated by capitalizing brand names. See also the list of the top 100 bestselling branded drugs, ranked by sales.
Tyson will once again use certain antibiotics in its chickens, eight years after it announced plans to ditch the drugs in some of its production and slapped a “no antibiotics ever” label on ...
This list is not limited to drugs that were ever approved by the FDA. Some of them (lumiracoxib, rimonabant, tolrestat, ximelagatran and ximelidine, for example) were approved to be marketed in Europe but had not yet been approved for marketing in the US, when side effects became clear and their developers pulled them from the market.